Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recMAGE-A3 + AS15 versus placebo after cystectomy in MAGE-A3-positive muscle-invasive bladder cancer
NL-OMON39841Phase 2Active, not recruiting
- Sponsor
- European Association of Urology
- Start
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bladder cancer comparing recMAGE-A3 + AS15 ASCI with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Jun 2012; status: active, not recruiting.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NL-OMON39841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39841.